Advaxis

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Advaxis ( ADXS) is a clinical development stage biotechnology company, developing safe and effective immunotherapies for cancer and infectious diseases with its lead construct, ADXS-HPV, being evaluated in five clinical trials for HPV-associated diseases. This stock closed up 3.7% to $3.87 in Tuesday's trading session.

Tuesday's Range: $3.72-$3.95
52-Week Range: $3.38-$3.95
Thursday's Volume: 516,000
Three-Month Average Volume: 199,533

>>5 Stocks Ready to Break Out

From a technical perspective, ADXS trended higher here with heavy upside volume. This stock recently gapped down sharply from around $5.50 to $3.50 with heavy downside volume. This stock went on to print a new low a few trading sessions later at $3.38. Following that gap down, shares of ADXS have now started to rebound off that $3.38 low and move within range of triggering a major breakout trade. That trade will hit if ADXS manages to take out Tuesday's high of $3.95 to $4 with high volume.

Traders should now look for long-biased trades in ADXS as long as it's trending above its recent low of $3.38 and then once it sustains a move or close above those breakout levels with volume that hits near or above 199,533 shares. If that breakout triggers soon, then ADXS will set up to re-fill some of its previous gap down zone that started near $5.50.

If you liked this article you might like

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

These 5 Stocks Under $10 Could Explode Up Soon

Think Big on These Small Biotechs

Don't Roll the Dice on Central Bank News

Amgen, Regeneron Forge New, Separate Cancer Immunotherapy Pacts